Buprenorphine Patch Use in Opioid-Dependent Patients

Critical Contraindications and Warnings

Opioid patches, including buprenorphine, are explicitly contraindicated in opioid-naive patients because they take too long to reach steady-state clinical effect and carry high morphine equivalence risk 1
The transdermal formulation has a delayed onset of action that makes it unsuitable for patients who have not been previously exposed to opioids or who require rapid dose titration 1
Buprenorphine should only be administered to patients in active opioid withdrawal as confirmed by history and physical examination using tools such as the Clinical Opiate Withdrawal Scale 2, 3
Particular caution is required when transitioning from methadone to buprenorphine due to risk of severe and prolonged precipitated withdrawal 2, 3

Buprenorphine transdermal patches can be considered as a therapeutic option in patients with stable chronic pain, particularly when oral administration is impossible due to uncontrolled nausea and vomiting 4
Buprenorphine transdermal patches can be considered for patients with risk of bowel obstruction, poor digestive absorption, or moderate chronic renal failure 4
For patients on sublingual buprenorphine/naloxone for opioid use disorder who develop chronic pain, consider switching to buprenorphine transdermal alone rather than adding the patch to existing therapy 5

Patient must be stabilized on sublingual/buccal buprenorphine for minimum 7 days before considering any transition to long-acting formulations, according to the American Society of Addiction Medicine 6, 7
Ensure patient is not experiencing withdrawal symptoms and is comfortable on their current dose, as recommended by the American Academy of Pain Medicine 6, 7

Because buprenorphine does not occupy all opioid receptors, other opioids can be given when pain is acute, as suggested by the American Pain Society 5
High-potency opioids such as fentanyl or hydromorphone should be considered when nonpharmacologic treatments and nonopioid pharmacotherapies are ineffective, according to the American Society of Regional Anesthesia and Pain Medicine 5

Be extremely cautious with patients who may require surgery, as buprenorphine's high binding affinity may interfere with perioperative pain management, as warned by the American Society of Anesthesiologists 6
Concomitant use with QT-prolonging agents is contraindicated, as advised by the National Institute of Health 6, 7